company background image
CPCI

Kahira Pharmaceuticals & Chemical IndustriesCASE:CPCI Stock Report

Market Cap

ج.م597.4m

7D

0%

1Y

5.6%

Updated

26 Oct, 2021

Data

Company Financials
CPCI fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance5/6
Financial Health5/6
Dividends2/6

CPCI Overview

Kahira Pharmaceuticals & Chemical Industries Company manufactures and sells pharmaceutical products in Egypt.

Price History & Performance

Summary of all time highs, changes and price drops for Kahira Pharmaceuticals & Chemical Industries
Historical stock prices
Current Share Priceج.م40.00
52 Week Highج.م34.20
52 Week Lowج.م42.99
Beta0.31
1 Month Change0%
3 Month Change5.51%
1 Year Change5.63%
3 Year Change18.32%
5 Year Change207.69%
Change since IPO8.87%

Recent News & Updates

Shareholder Returns

CPCIEG PharmaceuticalsEG Market
7D0%-5.4%3.0%
1Y5.6%-1.9%12.4%

Return vs Industry: CPCI exceeded the EG Pharmaceuticals industry which returned -1.9% over the past year.

Return vs Market: CPCI underperformed the EG Market which returned 12.4% over the past year.

Price Volatility

Is CPCI's price volatile compared to industry and market?
CPCI volatility
CPCI Beta0.31
Industry Beta0.84
Market Beta1

Stable Share Price: CPCI is less volatile than 75% of EG stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: CPCI's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19622,277Yasser Farghalihttps://www.kahira-pharma.com

Kahira Pharmaceuticals & Chemical Industries Company manufactures and sells pharmaceutical products in Egypt. Its products include analgesics antipyretics antirheumatic, antibiotics, antidepressants, antidysenterics and enterostatics, antiemetics, antihistamines, antimalarial, cardiacs vascularetics, dermatologicals, endocrine drugs, gastrointestinal drugs, haemostatics, ophthalmics, oro-dentals, pulmonics, single vitamins, sulfhanamides with trimethoprim, topical analgesic antirhumatics, urinary antiseptics, urologics, vaginetics, inhalation surgical products, nutrients, and vitamins and minerals. The company also manufactures veterinary products; and manufactures pharmaceutical products for underlicense companies.

Kahira Pharmaceuticals & Chemical Industries Fundamentals Summary

How do Kahira Pharmaceuticals & Chemical Industries's earnings and revenue compare to its market cap?
CPCI fundamental statistics
Market Capج.م597.38m
Earnings (TTM)ج.م124.30m
Revenue (TTM)ج.م1.06b

4.8x

P/E Ratio

0.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CPCI income statement (TTM)
Revenueج.م1.06b
Cost of Revenueج.م793.91m
Gross Profitج.م268.13m
Expensesج.م143.83m
Earningsج.م124.30m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)8.32
Gross Margin25.25%
Net Profit Margin11.70%
Debt/Equity Ratio0.7%

How did CPCI perform over the long term?

See historical performance and comparison

Dividends

6.7%

Current Dividend Yield

32%

Payout Ratio

Valuation

Is Kahira Pharmaceuticals & Chemical Industries undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CPCI (EGP40) is trading below our estimate of fair value (EGP178.19)

Significantly Below Fair Value: CPCI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CPCI is good value based on its PE Ratio (4.8x) compared to the EG Pharmaceuticals industry average (5.9x).

PE vs Market: CPCI is good value based on its PE Ratio (4.8x) compared to the EG market (11.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CPCI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CPCI is good value based on its PB Ratio (0.8x) compared to the EG Pharmaceuticals industry average (1.3x).


Future Growth

How is Kahira Pharmaceuticals & Chemical Industries forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kahira Pharmaceuticals & Chemical Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Kahira Pharmaceuticals & Chemical Industries performed over the past 5 years?

12.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CPCI has high quality earnings.

Growing Profit Margin: CPCI's current net profit margins (11.7%) are higher than last year (10.8%).


Past Earnings Growth Analysis

Earnings Trend: CPCI's earnings have grown by 12.4% per year over the past 5 years.

Accelerating Growth: CPCI's earnings growth over the past year (13.9%) exceeds its 5-year average (12.4% per year).

Earnings vs Industry: CPCI earnings growth over the past year (13.9%) exceeded the Pharmaceuticals industry 10%.


Return on Equity

High ROE: CPCI's Return on Equity (17.7%) is considered low.


Financial Health

How is Kahira Pharmaceuticals & Chemical Industries's financial position?


Financial Position Analysis

Short Term Liabilities: CPCI's short term assets (EGP915.5M) exceed its short term liabilities (EGP358.2M).

Long Term Liabilities: CPCI's short term assets (EGP915.5M) exceed its long term liabilities (EGP6.6M).


Debt to Equity History and Analysis

Debt Level: CPCI's debt to equity ratio (0.7%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if CPCI's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: CPCI's debt is well covered by operating cash flow (3302.5%).

Interest Coverage: CPCI earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Kahira Pharmaceuticals & Chemical Industries's current dividend yield, its reliability and sustainability?

6.70%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: CPCI's dividend (6.7%) is higher than the bottom 25% of dividend payers in the EG market (2.63%).

High Dividend: CPCI's dividend (6.7%) is low compared to the top 25% of dividend payers in the EG market (7.87%).


Stability and Growth of Payments

Stable Dividend: CPCI has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: CPCI's dividend payments have increased, but the company has only paid a dividend for 9 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (32.2%), CPCI's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Yasser Farghali

no data

Tenure

Dr. Yasser Ahmed Farghali is Executive Managing Director of Kahira Pharmaceuticals & Chemical Industries Company.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Kahira Pharmaceuticals & Chemical Industries Company's employee growth, exchange listings and data sources


Key Information

  • Name: Kahira Pharmaceuticals & Chemical Industries Company
  • Ticker: CPCI
  • Exchange: CASE
  • Founded: 1962
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ج.م597.375m
  • Shares outstanding: 14.93m
  • Website: https://www.kahira-pharma.com

Number of Employees


Location

  • Kahira Pharmaceuticals & Chemical Industries Company
  • 4 Abdel-Hamid Eldeeb Street
  • Victoria SQ
  • Cairo
  • Egypt

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 16:18
End of Day Share Price2021/10/26 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.